The aim of this study is to evaluate risk factors contributing to the development of ototoxicity in children who received platinum-based chemotherapy for malignancies located in the head and neck region. Eighty-four children who received platinum-based chemotherapy were included. Audiologic evaluations were performed before and after each chemotherapy session through pure tone audiometry, distortion product otoacoustic emissions, and auditory brainstem response tests. Ototoxicity was evaluated using Brock, Muenster, and Chang classifications. Factors such as cranial irradiation, cumulative doses of cisplatin, age, sex, cotreatment with aminoglycosides, schedule of platinum, and type of chemotherapeutic agent were analyzed. Using chi(2) test...
INTRODUCTION : The term chemotherapy was coined in the early 1900s and means- 'treating with chemic...
Ototoxicity (hearing loss, tinnitus and/or vertigo) is a serious adverse event of childhood cancer t...
Objective: To evaluate hearing impairment in children with cancer who received platinum compounds
The aim of this study is to evaluate risk factors contributing to the development of ototoxicity in ...
Platinum compounds constitute the standard treatment for solid tumors in pediatric oncology. The pur...
Approximately 550–600 children are diagnosed with cancer every year in the Netherlands. Improvements...
Platinum-containing chemotherapeutics are efficacious for a variety of pediatric malignancies, never...
Platinum-containing chemotherapeutics are efficacious for a variety of pediatric malignancies, never...
Background: Platinum compounds are a group of fundamental chemotherapeutics used in the treatment of...
Background Platinum-based therapy, including cisplatin, carboplatin, oxaliplatin or a combination of...
Platinum compounds are a group of chemotherapeutic agents included in many pediatric and adult onco...
<strong>Background: </strong>Since the establishment of oncology unit in Hospital Pulau Pinang, no s...
2019-04-17Ototoxicity induced by cisplatin therapy is a severe adverse effect, especially for childr...
Children treated for malignancies may be at risk for early- or delayed-onset hearing loss that can a...
Purpose Optimal assessment methods and criteria for reporting hearing outcomes in children who recei...
INTRODUCTION : The term chemotherapy was coined in the early 1900s and means- 'treating with chemic...
Ototoxicity (hearing loss, tinnitus and/or vertigo) is a serious adverse event of childhood cancer t...
Objective: To evaluate hearing impairment in children with cancer who received platinum compounds
The aim of this study is to evaluate risk factors contributing to the development of ototoxicity in ...
Platinum compounds constitute the standard treatment for solid tumors in pediatric oncology. The pur...
Approximately 550–600 children are diagnosed with cancer every year in the Netherlands. Improvements...
Platinum-containing chemotherapeutics are efficacious for a variety of pediatric malignancies, never...
Platinum-containing chemotherapeutics are efficacious for a variety of pediatric malignancies, never...
Background: Platinum compounds are a group of fundamental chemotherapeutics used in the treatment of...
Background Platinum-based therapy, including cisplatin, carboplatin, oxaliplatin or a combination of...
Platinum compounds are a group of chemotherapeutic agents included in many pediatric and adult onco...
<strong>Background: </strong>Since the establishment of oncology unit in Hospital Pulau Pinang, no s...
2019-04-17Ototoxicity induced by cisplatin therapy is a severe adverse effect, especially for childr...
Children treated for malignancies may be at risk for early- or delayed-onset hearing loss that can a...
Purpose Optimal assessment methods and criteria for reporting hearing outcomes in children who recei...
INTRODUCTION : The term chemotherapy was coined in the early 1900s and means- 'treating with chemic...
Ototoxicity (hearing loss, tinnitus and/or vertigo) is a serious adverse event of childhood cancer t...
Objective: To evaluate hearing impairment in children with cancer who received platinum compounds